NLRP3 and chronic kidney disease: These findings reveal a previously unrecognized HK1–glycolysis–NLRP3 pathway as a metabolic-inflammatory target and suggest that Irisin/HK1 modulation may represent a novel therapeutic strategy for CKD-related vascular calcification.